Shuaishuai Zhang

Dr. Shuaishuai Zhang

Institute for Brain Research and Rehabilitation, South China Normal University, Guangzhou, Guangdong, China
+1
orcid
Stay hungry, stay foolish

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2023 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
XCXiaohong Chen
Xiaohong Chen
SWShuang Wang
Shuang Wang
YCYuxuan Chen
Yuxuan Chen
HXHuhu Xin
Huhu Xin
Shuaishuai ZhangShuaishuai Zhang
Shuaishuai Zhang
YPYuan Ping
Yuan Ping

12 December 2023 in PeerJ
Verified
Journal Article
Open access
PDF file
SLShenjin Lai
Shenjin Lai
PWPeng Wang
Peng Wang
JGJingru Gong
Jingru Gong
Shuaishuai ZhangShuaishuai Zhang
Shuaishuai Zhang
Glycogen synthase kinase 3 (GSK-3) is a serine/threonine kinase widely expressed in various tissues and organs. Unlike other kinases, GSK-3 is active under resting conditions and is inactivated upon stimulation. In mammals, GSK-3 includes GSK-3 α and GSK-3β isoforms encoded by two homologous genes, namely, GSK3A and GSK3B. GSK-3β is essential for the control of glucose metabolism, signal transduction, and tissue homeostasis. As more than 100 known proteins have been identified as GSK-3β substrates, it is sometimes referred to as a moonlighting kinase. Previous studies have elucidated the regulation modes of GSK-3β. GSK-3β is involved in almost all aspects of brain functions, such as neuronal morphology, synapse formation, neuroinflammation, and neurological disorders. Recently, several comparatively specific small molecules have facilitated the chemical manipulation of this enzyme within cellular systems, leading to the discovery of novel inhibitors for GSK-3β. Despite these advancements, the therapeutic significance of GSK-3β as a drug target is still complicated by uncertainties surrounding the potential of inhibitors to stimulate tumorigenesis. This review provides a comprehensive overview of the intricate mechanisms of this enzyme and evaluates the existing evidence regarding the therapeutic potential of GSK-3β in brain diseases, including Alzheimer’s disease, Parkinson’s disease, mood disorders, and glioblastoma.

7 December 2021 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
LCLei Cao
Lei Cao
YZYuqin Zhu
Yuqin Zhu
WWWeiju Wang
Weiju Wang
GWGaoxiong Wang
Gaoxiong Wang
Shuaishuai ZhangShuaishuai Zhang
Shuaishuai Zhang
Hongwei ChengHongwei Cheng
Hongwei Cheng
Drug resistance is the most significant causes of cancer chemotherapy failure. Various mechanisms of drug resistance include tumor heterogeneity, tumor microenvironment, changes at cellular levels, genetic factors, and other mechanisms. In recent years, more attention has been paid to tumor resistance mechanisms and countermeasures. Nanomedicine is an emerging treatment platform, focusing on alternative drug delivery and improved therapeutic effectiveness while reducing side effects on normal tissues. Here, we reviewed the principal forms of drug resistance and the new possibilities that nanomaterials offer for overcoming these therapeutic barriers. Novel nanomaterials based on tumor types are an excellent modality to equalize drug resistance that enables gain more rational and flexible drug selectivity for individual patient treatment. With the emergence of advanced designs and alternative drug delivery strategies with different nanomaterials, overcome of multidrug resistance shows promising and opens new horizons for cancer therapy. This review discussed different mechanisms of drug resistance and recent advances in nanotechnology-based therapeutic strategies to improve the sensitivity and effectiveness of chemotherapeutic drugs, aiming to show the advantages of nanomaterials in overcoming of drug resistance for tumor chemotherapy, which could accelerate the development of personalized medicine.

1 January 2021 in Theranostics
Verified
Journal Article
Open access
ZSZeyu Shi
Zeyu Shi
STSally K. Y. To
Sally K. Y. To
Shuaishuai ZhangShuaishuai Zhang
Shuaishuai Zhang
SDShan Deng
Shan Deng
MAMargarita Artemenko
Margarita Artemenko
AWAlice Sze-Tsai Wong
Alice Sze-Tsai Wong
Background: Colorectal cancer (CRC) and the associated metastatic lesions are reported to be hypoxic. Hypoxia is a common feature in the tumor microenvironment and a potent stimulant of CRC. We have identified a regulatory role of Nur77 on Akt activation to enhance β-catenin signaling essential for CRC progression under hypoxic conditions.

27 December 2024 in Phytomedicine
Verified
Journal Article
Closed access
PWPeng Wang
Peng Wang
HOHui Ouyang
Hui Ouyang
GBGuofang Bi
Guofang Bi
FLFengting Liang
Fengting Liang
SHShuang Hu
Shuang Hu
HBHuichang Bi
Huichang Bi

16 January 2023 in Pharmacological Research
Verified
Journal Article
Open access
Shuaishuai ZhangShuaishuai Zhang
Shuaishuai Zhang
MGManlan Guo
Manlan Guo
XJXiaowen Jiang
Xiaowen Jiang
LTLan Tang
Lan Tang
TWTing Wu
Ting Wu
HBHuichang Bi
Huichang Bi
Pregnane X receptor (PXR) plays an important role in the regulation of metabolic homeostasis. Yes-associated protein (YAP) is a critical regulator of liver size and liver regeneration. Recently, we reported that PXR-induced liver enlargement and regeneration depend on YAP signalling, but the underlying mechanisms remain unclear. This study aimed to reveal how PXR regulates or interacts with YAP signalling during PXR-induced hepatomegaly and liver regeneration. Immunoprecipitation (IP), Co-IP and GST pull-down assays were performed in vitro to reveal the regulatory mechanisms involved in the PXR-YAP interaction. The roles of YAP-TEAD binding and Sirt2-driven deacetylation and polyubiquitination of YAP were further investigated in vitro and in vivo. The results showed that the ligand-binding domain (LBD) of PXR and the WW domain of YAP were critical for the PXR-YAP interaction. Furthermore, disruption of the YAP-TEAD interaction using the binding inhibitor verteporfin significantly decreased PXR-induced liver enlargement and regeneration after 70 % partial hepatectomy (PHx). Mechanistically, PXR activation significantly decreased YAP acetylation, which was interrupted by the sirtuin inhibitor nicotinamide (NAM). In addition, p300-induced YAP acetylation contributed to K48-linked YAP ubiquitination. Interestingly, PXR activation remarkably inhibited K48-linked YAP ubiquitination while inducing K63-linked YAP polyubiquitination. Sirt2 interference abolished the deacetylation and K63-linked polyubiquitination of YAP, suggesting that the PXR-induced deacetylation and polyubiquitination of YAP are Sirt2 dependent. Taken together, this study demonstrates that PXR induce liver enlargement and regeneration via the regulation of YAP acetylation and ubiquitination and YAP-TEAD binding, providing evidences for using PXR as potential target to promote hepatic development and liver repair.